{"id":29,"date":"2008-08-25T15:44:54","date_gmt":"2008-08-25T19:44:54","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/cto\/sickle-cell-disease\/"},"modified":"2024-09-26T09:51:11","modified_gmt":"2024-09-26T13:51:11","slug":"sickle-cell-disease","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/sickle-cell-disease\/","title":{"rendered":"Sickle Cell Disease"},"content":{"rendered":"<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04084080?term=NCT04084080&amp;draw=2&amp;rank=1\"><strong>Central IRB #H-39846\/ NHLB #SCD-CARRE<\/strong>:<\/a> <strong>S<\/strong>ickle <strong>C<\/strong>ell <strong>D<\/strong>isease &amp; <strong>C<\/strong>ardiov<strong>A<\/strong>scular <strong>R<\/strong>isk &#8211; <strong>R<\/strong>ed cell <strong>E<\/strong>xchange Trial<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04624659?term=NCT04624659&amp;draw=2&amp;rank=1\"><strong>Central IRB #H-40856\/ Forma\/Novo Nordisk #4202-HEM-301 (HIBISCUS)<\/strong>:<\/a> An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (HIBISCUS)<\/p>\n<p><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05169580?term=NCT05169580&amp;rank=1\"><strong>Central IRB #H-44795\/ Fulcrum #6058-SCD-101<\/strong>:<\/a> A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD)<\/p>\n<p><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06609226?term=NCT06609226&amp;rank=1\"><strong>Central IRB #pend\/ Novo Nordisk #NN7535-7822 (FLORAL)<\/strong>:<\/a> An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study <b>(pending IRB)<\/b><\/p>\n<p><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06286046?term=NCT06286046&amp;rank=1\"><strong>Central IRB #H-45056\/ Agios #AG348-C-026<\/strong>:<\/a> A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy <b>(pending)<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Central IRB #H-39846\/ NHLB #SCD-CARRE: Sickle Cell Disease &amp; CardiovAscular Risk &#8211; Red cell Exchange Trial Central IRB #H-40856\/ Forma\/Novo Nordisk #4202-HEM-301 (HIBISCUS): An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Agonist in Patients with Sickle Cell Disease (HIBISCUS) Central IRB #H-44795\/ Fulcrum #6058-SCD-101: A Phase 1 Open-Label, Multiple-Dose Study [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":19,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/29"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/comments?post=29"}],"version-history":[{"count":51,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/29\/revisions"}],"predecessor-version":[{"id":5505,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/29\/revisions\/5505"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/media?parent=29"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}